全文获取类型
收费全文 | 152574篇 |
免费 | 12348篇 |
国内免费 | 332篇 |
专业分类
耳鼻咽喉 | 1390篇 |
儿科学 | 4519篇 |
妇产科学 | 3382篇 |
基础医学 | 23601篇 |
口腔科学 | 3760篇 |
临床医学 | 14508篇 |
内科学 | 31014篇 |
皮肤病学 | 2814篇 |
神经病学 | 14909篇 |
特种医学 | 6081篇 |
外国民族医学 | 20篇 |
外科学 | 18436篇 |
综合类 | 759篇 |
现状与发展 | 1篇 |
一般理论 | 113篇 |
预防医学 | 17017篇 |
眼科学 | 2314篇 |
药学 | 9397篇 |
中国医学 | 261篇 |
肿瘤学 | 10958篇 |
出版年
2023年 | 743篇 |
2022年 | 565篇 |
2021年 | 2504篇 |
2020年 | 2056篇 |
2019年 | 3031篇 |
2018年 | 3686篇 |
2017年 | 3057篇 |
2016年 | 3282篇 |
2015年 | 3652篇 |
2014年 | 4835篇 |
2013年 | 6416篇 |
2012年 | 9480篇 |
2011年 | 9430篇 |
2010年 | 5104篇 |
2009年 | 5240篇 |
2008年 | 8332篇 |
2007年 | 8504篇 |
2006年 | 8162篇 |
2005年 | 7712篇 |
2004年 | 6671篇 |
2003年 | 6243篇 |
2002年 | 5708篇 |
2001年 | 4766篇 |
2000年 | 4738篇 |
1999年 | 4222篇 |
1998年 | 1768篇 |
1997年 | 1442篇 |
1996年 | 1486篇 |
1995年 | 1372篇 |
1994年 | 1262篇 |
1993年 | 1141篇 |
1992年 | 2866篇 |
1991年 | 2604篇 |
1990年 | 2495篇 |
1989年 | 2332篇 |
1988年 | 2126篇 |
1987年 | 1871篇 |
1986年 | 1801篇 |
1985年 | 1710篇 |
1984年 | 1233篇 |
1983年 | 1069篇 |
1982年 | 626篇 |
1981年 | 554篇 |
1980年 | 457篇 |
1979年 | 915篇 |
1978年 | 571篇 |
1977年 | 490篇 |
1974年 | 482篇 |
1973年 | 456篇 |
1972年 | 407篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
73.
74.
75.
76.
Baten Abdul Wallemacq Pascaline van Loenhout Joris Adriaan Frank Guha-Sapir Debarati 《Maternal and child health journal》2020,24(6):748-758
Maternal and Child Health Journal - Floods are one of the most common types of disasters in Bangladesh and lead to direct and indirect impacts on health. The aim of the study was to assess the... 相似文献
77.
Sanne C. F. A. Huijberts Robin M. J. M. van Geel Emilie M. J. van Brummelen Frans L. Opdam Serena Marchetti Neeltje Steeghs Saskia Pulleman Bas Thijssen Hilde Rosing Kim Monkhorst Alwin D. R. Huitema Jos H. Beijnen Ren Bernards Jan H. M. Schellens 《Cancer chemotherapy and pharmacology》2020,85(5):917-930
KRAS oncogene mutations cause sustained signaling through the MAPK pathway. Concurrent inhibition of MEK, EGFR, and HER2 resulted in complete inhibition of tumor growth in KRAS-mutant (KRASm) and PIK3CA wild-type tumors, in vitro and in vivo. In this phase I study, patients with advanced KRASm and PIK3CA wild-type colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancer, were treated with combined lapatinib and trametinib to assess the recommended phase 2 regimen (RP2R). Patients received escalating doses of continuous or intermittent once daily (QD) orally administered lapatinib and trametinib, starting at 750 mg and 1 mg continuously, respectively. Thirty-four patients (16 CRC, 15 NSCLC, three pancreatic cancers) were enrolled across six dose levels and eight patients experienced dose-limiting toxicities, including grade 3 diarrhea (n = 2), rash (n = 2), nausea (n = 1), multiple grade 2 toxicities (n = 1), and aspartate aminotransferase elevation (n = 1), resulting in the inability to receive 75% of planned doses (n = 2) or treatment delay (n = 2). The RP2R with continuous dosing was 750 mg lapatinib QD plus 1 mg trametinib QD and with intermittent dosing 750 mg lapatinib QD and trametinib 1.5 mg QD 5 days on/2 days off. Regression of target lesions was seen in 6 of the 24 patients evaluable for response, with one confirmed partial response in NSCLC. Pharmacokinetic results were as expected. Lapatinib and trametinib could be combined in an intermittent dosing schedule in patients with manageable toxicity. Preliminary signs of anti-tumor activity in NSCLC have been observed and pharmacodynamic target engagement was demonstrated. 相似文献
78.
Mark P. van Opijnen Linda Dirven Ida E.M. Coremans Martin J.B. Taphoorn Ellen H.W. Kapiteijn 《International journal of cancer. Journal international du cancer》2020,146(6):1479-1489
Patients with melanoma brain metastases (MBM) still have a very poor prognosis. Several treatment modalities have been investigated in an attempt to improve the management of MBM. This review aimed to evaluate the impact of current treatments for MBM on patient- and tumor-related outcomes, and to provide treatment recommendations for this patient population. A literature search in the databases PubMed, Embase, Web of Science and Cochrane was conducted up to January 8, 2019. Original articles published since 2010 describing patient- and tumor-related outcomes of adult MBM patients treated with clearly defined systemic therapy were included. Information on basic trial demographics, treatment under investigation and outcomes (overall and progression-free survival, local and distant control and toxicity) were extracted. We identified 96 eligible articles, comprising 95 studies. A large variety of treatment options for MBM were investigated, either used alone or as combined modality therapy. Combined modality therapy was investigated in 71% of the studies and resulted in increased survival and better distant/local control than monotherapy, especially with targeted therapy or immunotherapy. However, neurotoxic side-effects also occurred more frequently. Timing appeared to be an important determinant, with the best results when radiotherapy was given before or during systemic therapy. Improved tumor control and prolonged survival can be achieved by combining radiotherapy with immunotherapy or targeted therapy. However, more randomized controlled trials or prospective studies are warranted to generate proper evidence that can be used to change the standard of care for patients with MBM. 相似文献
79.
Norah Anthony Delphine Bourneau-martin Sarah Ghamrawi Laurence Lagarce Marina Babin Marie Briet 《Fundamental & clinical pharmacology》2020,34(6):736-742
Vitiligo is a common depigmenting disorder ensuing the loss of epidermal melanocytes. It is a multifactorial disease with immunological, genetic and environmental factors including drug exposure. The purpose of the study was to investigate the drugs and therapeutic subclasses associated with vitiligo occurrence reported in VigiBase®, the WHO pharmacovigilance database. A case/non-case study was carried out by defining cases as vitiligo reports and non-cases as all other reports. The reporting odds ratio (ROR) was calculated for the ‘suspected’ drugs and drug classes according to ATC level 4. During the study period, 741 cases of vitiligo were registered. Mean age was 49 ± 20 years. The disproportionality analysis showed an association between vitiligo and pembrolizumab (ROR 116.9, 95% Confidence Interval (CI) 94.8, 144.3), nivolumab (ROR 22.6, 95% CI 15.8, 32.4), ipilimumab (ROR 41.7, 95% CI 25.0, 69.7), imiquimod (ROR 152.8, 95% CI 103.0, 226.7), adalimumab (ROR 3.8, 95% CI 2.5,5.8), infliximab (ROR 2.6, 95% CI 1.65, 4.01), alemtuzumab (ROR 27.8, 95% CI 17.6, 43.9), and ustekinumab (ROR 9.3, 95% CI 5.6, 15.6). Concerning the pharmacological classes ATC level 4, a significant association was found with monoclonal antibodies, interferons, selective immunosuppressants, TNF-alpha inhibitors, interleukin inhibitors, and topical antivirals. This study confirmed the expected associations between vitiligo and immune checkpoint inhibitors and strengthened the emerging signal about the association between vitiligo and imiquimod, TNF-alpha inhibitors and interferons. New signals were shown with selective immunosuppressants including alemtuzumab and interleukin inhibitors. 相似文献